- Home
- AGEN vs FATE Comparison
AGEN vs FATE Comparison
Compare AGEN & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | FATE |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 139.6M |
| IPO Year | 1999 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AGEN | FATE |
|---|---|---|
| Price | $3.16 | $1.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $14.50 | $4.10 |
| AVG Volume (30 Days) | 372.3K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $42,877,086.00 | $6,646,000.00 |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $68.25 | $1.05 |
| P/E Ratio | $8.04 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $1.38 | $0.66 |
| 52 Week High | $7.34 | $1.94 |
Technical Indicators
Market Signals| Indicator | AGEN | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 50.14 |
| Support Level | $2.90 | $0.96 |
| Resistance Level | $3.38 | $1.35 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 52.69 | 18.40 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.